Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Quantifying transmissibility and dispersion of SARS-CoV-2 variants and subvariants of concern in England

View ORCID ProfileBen Swallow, Joshua Grier, Jasmina Panovska-Griffiths
doi: https://doi.org/10.1101/2024.08.14.24311985
Ben Swallow
1School of Mathematics and Statistics, University of St Andrews, UK
2Centre for Research into Ecological and Environmental Modelling, University of St Andrews, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Swallow
  • For correspondence: bts3{at}st-andrews.ac.uk
Joshua Grier
3University College, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasmina Panovska-Griffiths
4The Queens College, University of Oxford, UK
5The Big Data Institute and the Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The SARS-CoV-2 pandemic was characterised by continual emergence of variants. For improved future pandemic preparedness it is important to understand whether each successive variant has been more infectious and more widely spread. In this paper, we used genetic sequencing data from the COVID-19 Genomics UK Consortium in England and robust statistical models to quantify transmissibility advantage and spatial heterogeneity of successive SARS-CoV-2 variants and their sub-variants circulating between September 2020 and December 2022.

Our results show that each variant was progressively more transmissible and more heterogeneously spread. Alpha was 10-40% more transmissible than B.1.177, Delta was 40-100% more transmissible than Alpha, and Omicron was 80-120% more transmissible than the Delta variant. Progressive variants were also more spatially heterogeneous: Alpha was mostly clustered in London and Southeast England, Delta was less clustered and prevalent in both Northwest and Southeast England, while Omicron was dispersed across the country. Successive sub-variants of different clade were more transmissible and spatially spread than the previous ones (e.g. the Omicron BA.1.1 variant was 20-60% more transmissible than the previous Delta AY.4 variant). However, sub-variants of the same clade didn’t differ in transmissibility or spatial spread. Our study improves understanding of transmission intensity and spatial heterogeneity across SARS-CoV-2 variants.

Ascertaining the threat posed by emerging variants and across infectious diseases is crucial to be better prepared for the next pandemic. Our method provides a tool for analysis of variant surveillance data, translatable across pathogens and settings, that can capture an emerging variant early and as part of the pandemic preparedness strategy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Source data were available at https://covid19.sanger.ac.uk/lineages/raw without limitation prior to the start of this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Data and code to reproduce the analyses and figures presented in the paper are available at the author github without restriction.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 17, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantifying transmissibility and dispersion of SARS-CoV-2 variants and subvariants of concern in England
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quantifying transmissibility and dispersion of SARS-CoV-2 variants and subvariants of concern in England
Ben Swallow, Joshua Grier, Jasmina Panovska-Griffiths
medRxiv 2024.08.14.24311985; doi: https://doi.org/10.1101/2024.08.14.24311985
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Quantifying transmissibility and dispersion of SARS-CoV-2 variants and subvariants of concern in England
Ben Swallow, Joshua Grier, Jasmina Panovska-Griffiths
medRxiv 2024.08.14.24311985; doi: https://doi.org/10.1101/2024.08.14.24311985

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)